A citation-based method for searching scientific literature

Jesper Jensen, Massar Omar, Caroline Kistorp, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Julie L Forman, Jacob E Møller, Morten Schou. Circulation 2021
Times Cited: 6







List of co-cited articles
40 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
83

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
83

Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction.
Massar Omar, Jesper Jensen, Peter H Frederiksen, Caroline Kistorp, Lars Videbæk, Mikael Kjær Poulsen, Sören Möller, Mulham Ali, Finn Gustafsson, Lars Køber,[...]. J Am Coll Cardiol 2020
29
83

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, Kenneth Mangion, Giles Roditi, Ross T Campbell, Colin Berry, Victor Chong, Liz Coyle, Kieran F Docherty,[...]. Circulation 2021
122
83

Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Jesper Jensen, Massar Omar, Caroline Kistorp, Mikael Kjær Poulsen, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Emil L Fosbøl,[...]. Am Heart J 2020
36
83

Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jesper Jensen, Massar Omar, Caroline Kistorp, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Mariam Elmegaard Malik, Emil Loldrup Fosbøl,[...]. Lancet Diabetes Endocrinol 2021
44
83

Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Massar Omar, Jesper Jensen, Mulham Ali, Peter H Frederiksen, Caroline Kistorp, Lars Videbæk, Mikael Kjær Poulsen, Christian D Tuxen, Sören Möller, Finn Gustafsson,[...]. JAMA Cardiol 2021
40
66

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
517
66

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
66

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, João P Ferreira, Edimar Bocchi, Michael Böhm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela,[...]. N Engl J Med 2021
605
66

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Carlos G Santos-Gallego, Ariana P Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna Mancini, Sean Pinney, Frank Macaluso, Samantha Sartori, Merce Roque, Fernando Sabatel-Perez,[...]. J Am Coll Cardiol 2021
139
66

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
50

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Jesper Jensen, Massar Omar, Caroline Kistorp, Mikael Kjær Poulsen, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Emil Fosbøl, Niels Eske Bruun,[...]. Trials 2019
29
50

Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
Natalie A Mordi, Ify R Mordi, Jagdeep S Singh, Rory J McCrimmon, Allan D Struthers, Chim C Lang. Circulation 2020
79
50

Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
Kevin Damman, Joost C Beusekamp, Eva M Boorsma, Henk P Swart, Tom D J Smilde, Arif Elvan, J W Martijn van Eck, Hiddo J L Heerspink, Adriaan A Voors. Eur J Heart Fail 2020
139
50

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
478
50

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
293
50

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
295
50

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Chioncel,[...]. Eur Heart J 2021
50

Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
Matthew Griffin, Veena S Rao, Juan Ivey-Miranda, James Fleming, Devin Mahoney, Christopher Maulion, Nisha Suda, Krishmita Siwakoti, Tariq Ahmad, Daniel Jacoby,[...]. Circulation 2020
138
50

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal,[...]. Lancet 2020
447
50

Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial.
Jawad H Butt, Jose C Nicolau, Subodh Verma, Kieran F Docherty, Mark C Petrie, Silvio E Inzucchi, Morten Schou, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez,[...]. Eur J Heart Fail 2021
14
33

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
33

Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
Alberto Aimo, Hanna K Gaggin, Andrea Barison, Michele Emdin, James L Januzzi. JACC Heart Fail 2019
56
33

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart J Pocock, Peter Carson, Inder Anand, Wolfram Doehner, Markus Haass,[...]. Circulation 2021
88
33

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Paul A Heidenreich, Biykem Bozkurt, David Aguilar, Larry A Allen, Joni J Byun, Monica M Colvin, Anita Deswal, Mark H Drazner, Shannon M Dunlay, Linda R Evers,[...]. J Am Coll Cardiol 2022
24
33

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
33

Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
Michael E Nassif, Mohammed Qintar, Sheryl L Windsor, Rita Jermyn, David M Shavelle, Fengming Tang, Sumant Lamba, Kunjan Bhatt, John Brush, Andrew Civitello,[...]. Circulation 2021
55
33

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Michael E Nassif, Sheryl L Windsor, Fengming Tang, Yevgeniy Khariton, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin,[...]. Circulation 2019
185
33

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Carlos G Santos-Gallego, Juan Antonio Requena-Ibanez, Rodolfo San Antonio, Kiyotake Ishikawa, Shin Watanabe, Belen Picatoste, Eduardo Flores, Alvaro Garcia-Ropero, Javier Sanz, Roger J Hajjar,[...]. J Am Coll Cardiol 2019
246
33

Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.
Juan Antonio Requena-Ibáñez, Carlos G Santos-Gallego, Anderly Rodriguez-Cordero, Ariana P Vargas-Delgado, Donna Mancini, Samantha Sartori, Farah Atallah-Lajam, Chiara Giannarelli, Frank Macaluso, Anuradha Lala,[...]. JACC Heart Fail 2021
41
33

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
326
33

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.
Eva M Boorsma, Joost C Beusekamp, Jozine M Ter Maaten, Sylwia M Figarska, A H Jan Danser, Dirk J van Veldhuisen, Peter van der Meer, Hiddo J L Heerspink, Kevin Damman, Adriaan A Voors. Eur J Heart Fail 2021
32
33

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, Nikolaus Marx, Carolyn S P Lam, Sven Schnaidt, Anne Pernille Ofstad, Martina Brueckmann, Waheed Jamal,[...]. Circulation 2021
97
33

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
Milton Packer, Javed Butler, Faiez Zannad, Gerasimos Filippatos, Joao Pedro Ferreira, Stuart J Pocock, Peter Carson, Inder Anand, Wolfram Doehner, Markus Haass,[...]. Circulation 2021
58
33

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
Michael E Nassif, Sheryl L Windsor, Barry A Borlaug, Dalane W Kitzman, Sanjiv J Shah, Fengming Tang, Yevgeniy Khariton, Ali O Malik, Taiyeb Khumri, Guillermo Umpierrez,[...]. Nat Med 2021
80
33

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
Scott D Solomon, Rudolf A de Boer, David DeMets, Adrian F Hernandez, Silvio E Inzucchi, Mikhail N Kosiborod, Carolyn S P Lam, Felipe Martinez, Sanjiv J Shah, Daniel Lindholm,[...]. Eur J Heart Fail 2021
69
33

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Adriaan A Voors, Christiane E Angermann, John R Teerlink, Sean P Collins, Mikhail Kosiborod, Jan Biegus, João Pedro Ferreira, Michael E Nassif, Mitchell A Psotka, Jasper Tromp,[...]. Nat Med 2022
45
33

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
Liang Xu, Naoto Nagata, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, Guanliang Chen, Eric Mayoux, Shuichi Kaneko, Tsuguhito Ota. EBioMedicine 2017
189
33

Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.
Ida Pernicova, Stephen Kelly, Sharon Ajodha, Anju Sahdev, Jonathan P Bestwick, Plamena Gabrovska, Olufunso Akanle, Ramzi Ajjan, Blerina Kola, Marietta Stadler,[...]. Lancet Diabetes Endocrinol 2020
30
16

The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients.
Greisa Vila, Michaela Riedl, Christian Anderwald, Michael Resl, Ammon Handisurya, Martin Clodi, Gerhard Prager, Bernhard Ludvik, Michael Krebs, Anton Luger. Clin Chem 2011
102
16

GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance.
Harding H Luan, Andrew Wang, Brandon K Hilliard, Fernando Carvalho, Connor E Rosen, Amy M Ahasic, Erica L Herzog, Insoo Kang, Margaret A Pisani, Shuang Yu,[...]. Cell 2019
184
16

High-Output Heart Failure: A 15-Year Experience.
Yogesh N V Reddy, Vojtech Melenovsky, Margaret M Redfield, Rick A Nishimura, Barry A Borlaug. J Am Coll Cardiol 2016
127
16

The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases.
Vicky W W Tsai, Yasmin Husaini, Amanda Sainsbury, David A Brown, Samuel N Breit. Cell Metab 2018
158
16

The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes.
Xingxing He, Jiaorong Su, Xiaojing Ma, Wei Lu, Wei Zhu, Yufei Wang, Yuqian Bao, Jian Zhou. Cardiovasc Diabetol 2020
15
16

GDF15 mediates the effects of metformin on body weight and energy balance.
Anthony P Coll, Michael Chen, Pranali Taskar, Debra Rimmington, Satish Patel, John A Tadross, Irene Cimino, Ming Yang, Paul Welsh, Samuel Virtue,[...]. Nature 2020
182
16

Growth/differentiation factor-15 (GDF-15) as a predictor of serious arrhythmic events in patients with nonischemic dilated cardiomyopathy.
Bruna Miers May, Adriano Nunes Kochi, Ana Paula Arbo Magalhães, Fernando Scolari, André Zimerman, Michael Andrades, Leandro I Zimerman, Luis E Rohde, Mauricio Pimentel. J Electrocardiol 2022
3
33

Increased Serum GDF15 Related to Improvement in Metabolism by Lifestyle Intervention Among Young Overweight and Obese Adults.
Lingli Cai, Cheng Li, Yufei Wang, Yifei Mo, Jun Yin, Xiaojing Ma. Diabetes Metab Syndr Obes 2021
4
25

Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis.
Hyo Kyun Chung, Dongryeol Ryu, Koon Soon Kim, Joon Young Chang, Yong Kyung Kim, Hyon-Seung Yi, Seul Gi Kang, Min Jeong Choi, Seong Eun Lee, Saet-Byel Jung,[...]. J Cell Biol 2017
174
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.